Regulus Therapeutics RGLS Stock
Regulus Therapeutics Price Chart
Regulus Therapeutics RGLS Financial and Trading Overview
| Regulus Therapeutics stock price | 2.55 USD |
| Previous Close | 1.41 USD |
| Open | 1.46 USD |
| Bid | 0 USD x 4000 |
| Ask | 0 USD x 4000 |
| Day's Range | 1.36 - 1.47 USD |
| 52 Week Range | 0.76 - 3 USD |
| Volume | 18.13K USD |
| Avg. Volume | 68.6K USD |
| Market Cap | 28.04M USD |
| Beta (5Y Monthly) | 1.542253 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.82 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 5.5 USD |
RGLS Valuation Measures
| Enterprise Value | 3.91M USD |
| Trailing P/E | N/A |
| Forward P/E | -1.2 |
| PEG Ratio (5 yr expected) | -0.02 |
| Price/Sales (ttm) | N/A |
| Price/Book (mrq) | 0.91312623 |
| Enterprise Value/Revenue | N/A |
| Enterprise Value/EBITDA | -0.135 |
Trading Information
Regulus Therapeutics Stock Price History
| Beta (5Y Monthly) | 1.542253 |
| 52-Week Change | -50.34% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 3 USD |
| 52 Week Low | 0.76 USD |
| 50-Day Moving Average | 1.34 USD |
| 200-Day Moving Average | 1.45 USD |
RGLS Share Statistics
| Avg. Volume (3 month) | 68.6K USD |
| Avg. Daily Volume (10-Days) | 30.54K USD |
| Shares Outstanding | 19.48M |
| Float | 15.58M |
| Short Ratio | 4.85 |
| % Held by Insiders | 4.95% |
| % Held by Institutions | 51.39% |
| Shares Short | 210.34K |
| Short % of Float | 1.40% |
| Short % of Shares Outstanding | 1.08% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor | 1:10 |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | 0% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -37.039% |
| Return on Equity (ttm) | -75.80% |
Income Statement
| Revenue (ttm) | N/A |
| Revenue Per Share (ttm) | N/A |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | -18410000 USD |
| EBITDA | -28895000 USD |
| Net Income Avi to Common (ttm) | -28743000 USD |
| Diluted EPS (ttm) | -1.81 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 30.31M USD |
| Total Cash Per Share (mrq) | 1.56 USD |
| Total Debt (mrq) | 5.98M USD |
| Total Debt/Equity (mrq) | 22.48 USD |
| Current Ratio (mrq) | 3.918 |
| Book Value Per Share (mrq) | 1.577 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -27259000 USD |
| Levered Free Cash Flow (ttm) | -16179125 USD |
Profile of Regulus Therapeutics
| Country | United States |
| State | CA |
| City | San Diego |
| Address | 4224 Campus Point Court |
| ZIP | 92121 |
| Phone | 858 202 6300 |
| Website | https://www.regulusrx.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 31 |
Regulus Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RG-012, an anti-miR targeting miR-21 that is in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease; and RGLS8429, an anti-miR targeting miR-17, which is in Phase 1b clinical study for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug products for target organ-selective delivery strategies. Regulus Therapeutics Inc. was incorporated in 2007 and is headquartered in San Diego, California.
Q&A For Regulus Therapeutics Stock
What is a current RGLS stock price?
Regulus Therapeutics RGLS stock price today per share is 2.55 USD.
How to purchase Regulus Therapeutics stock?
You can buy RGLS shares on the NasdaqCM exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Regulus Therapeutics?
The stock symbol or ticker of Regulus Therapeutics is RGLS.
Which industry does the Regulus Therapeutics company belong to?
The Regulus Therapeutics industry is Biotechnology.
How many shares does Regulus Therapeutics have in circulation?
The max supply of Regulus Therapeutics shares is 66.24M.
What is Regulus Therapeutics Price to Earnings Ratio (PE Ratio)?
Regulus Therapeutics PE Ratio is now.
What was Regulus Therapeutics earnings per share over the trailing 12 months (TTM)?
Regulus Therapeutics EPS is -0.82 USD over the trailing 12 months.
Which sector does the Regulus Therapeutics company belong to?
The Regulus Therapeutics sector is Healthcare.
Regulus Therapeutics RGLS included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| NASDAQ Composite IXIC | 16708.05 USD — |
+2.5
|
7.57B USD — | 16642.66 USD — | 17029.86 USD — | — - | 7.57B USD — |
| NASDAQ Capital Market Composite RCMP | 100.7 USD — |
+1.49
|
— — | 100.43 USD — | 103.32 USD — | — - | — — |
| NASDAQ HealthCare IXHC | 911.61 USD — |
+1.7
|
— — | 909.68 USD — | 929.8 USD — | — - | — — |
| NASDAQ Composite Total Return I XCMP | 20452.28 USD — |
+2.5
|
— — | 20372.24 USD — | 20846.21 USD — | — - | — — |
| NASDAQ Biotechnology Total Retu XNBI | 4453.6 USD — |
+1.68
|
— — | 4437.49 USD — | 4530.28 USD — | — - | — — |
- {{ link.label }} {{link}}